论文部分内容阅读
法制晚报讯(记者毛占宇)为何“印度版抗癌药”价格如此低廉?日前,记者采访了多名医药界人士,了解到其中原因:靶向抗癌药均为进口,专利费用高昂。而印度政府从保护国民公共健康角度出发,制定法律放宽本国药企仿造抗癌药的条件,导致成本大降。知识产权专家表示,药物强制许可政策最大受益者是贫困病人,药企生产仿制药的利润可能不高,国内药企
Legal News Evening News (Reporter Mao Zhanyu) Why “Indian version of anticancer drugs ” so cheap? Recently, the reporter interviewed a number of medical professionals, understand the reasons: targeted anti-cancer drugs are imported, expensive patent. The Indian government from the perspective of public health protection, the enactment of laws to relax the conditions of their own pharmaceutical companies imitation anticancer drugs, resulting in significant cost reduction. Intellectual property experts said that the biggest beneficiary of drug compulsory licensing policy is poor patients, pharmaceutical companies may not be profitable in the production of generic drugs, domestic pharmaceutical companies